Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivoligide for postoperative pain in TKA patients with high pain catastrophizing
NCT03797612Phase 2Withdrawn
- Sponsor
- Adynxx, Inc.
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postoperative pain comparing Brivoligide with Placebo (2 arms). Primary endpoint: Numerical Rating Scale (NRS) Pain with Walking 15 Meters. Planned start Jan 2021; status: withdrawn.
02
Drugs
brivoligide
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03797612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797612.